Literature DB >> 12807364

Costs of bipolar disorder.

Leah Kleinman1, Ana Lowin, Emuella Flood, Gian Gandhi, Eric Edgell, Dennis Revicki.   

Abstract

Bipolar disorder is a chronic affective disorder that causes significant economic burden to patients, families and society. It has a lifetime prevalence of approximately 1.3%. Bipolar disorder is characterised by recurrent mania or hypomania and depressive episodes that cause impairments in functioning and health-related quality of life. Patients require acute and maintenance therapy delivered via inpatient and outpatient treatment. Patients with bipolar disorder often have contact with the social welfare and legal systems; bipolar disorder impairs occupational functioning and may lead to premature mortality through suicide. This review examines the symptomatology of bipolar disorder and identifies those features that make it difficult and costly to treat. Methods for assessing direct and indirect costs are reviewed. We report on comprehensive cost studies as well as administrative claims data and program evaluations. The majority of data is drawn from studies conducted in the US; however, we discuss European studies when appropriate. Only two comprehensive cost-of-illness studies on bipolar disorder, one prevalence-based and one incidence-based, have been reported. There are, however, several comprehensive cost-of-illness studies measuring economic burden of affective disorders including bipolar disorder. Estimates of total costs of affective disorders in the US range from $US30.4-43.7 billion (1990 values). In the prevalence-based cost-of-illness study on bipolar disorder, total annual costs were estimated at $US45.2 billion (1991 values). In the incidence-based study, lifetime costs were estimated at $US24 billion. Although there have been recent advances in pharmacotherapy and outpatient therapy, hospitalisation still accounts for a substantial portion of the direct costs. A variety of outpatient services are increasingly important for the care of patients with bipolar disorder and costs in this area continue to grow. Indirect costs due to morbidity and premature mortality comprise a large portion of the cost of illness. Lost workdays or inability to work due to the disease cause high morbidity costs. Intangible costs such as family burden and impaired health-related quality of life are common, although it has proved difficult to attach monetary values to these costs.

Entities:  

Mesh:

Year:  2003        PMID: 12807364     DOI: 10.2165/00019053-200321090-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  76 in total

1.  Health care utilization and costs among patients treated for bipolar disorder in an insured population.

Authors:  G E Simon; J Unützer
Journal:  Psychiatr Serv       Date:  1999-10       Impact factor: 3.084

2.  Suicide and bipolar disorders.

Authors:  K R Jamison
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

3.  Cost-of-illness methodology: a guide to current practices and procedures.

Authors:  T A Hodgson; M R Meiners
Journal:  Milbank Mem Fund Q Health Soc       Date:  1982

4.  Suicide attempts, age and duration of illness in recurrent affective disorders.

Authors:  B Ahrens; A Berghöfer; T Wolf; B Müller-Oerlinghausen
Journal:  J Affect Disord       Date:  1995-12-24       Impact factor: 4.839

5.  Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles.

Authors:  M E Thase; D J Buysse; E Frank; C R Cherry; C L Cornes; A G Mallinger; D J Kupfer
Journal:  Am J Psychiatry       Date:  1997-04       Impact factor: 18.112

Review 6.  Prophylaxis of bipolar disorder: how and who should we treat in the long term?

Authors:  G M Goodwin
Journal:  Eur Neuropsychopharmacol       Date:  1999-08       Impact factor: 4.600

7.  Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.

Authors:  Dennis A Revicki; L Clark Paramore; Kenneth W Sommerville; Alan C Swann; John M Zajecka
Journal:  J Clin Psychiatry       Date:  2003-03       Impact factor: 4.384

8.  Outcome of bipolar disorder on long-term treatment with lithium.

Authors:  R A O'Connell; J A Mayo; L Flatow; B Cuthbertson; B E O'Brien
Journal:  Br J Psychiatry       Date:  1991-07       Impact factor: 9.319

9.  The emerging epidemiology of hypomania and bipolar II disorder.

Authors:  J Angst
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

10.  Symptoms and functioning of patients with bipolar disorder six months after hospitalization.

Authors:  G L Dion; M Tohen; W A Anthony; C S Waternaux
Journal:  Hosp Community Psychiatry       Date:  1988-06
View more
  65 in total

1.  Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.

Authors:  Ronald C Kessler; Hagop S Akiskal; Minnie Ames; Howard Birnbaum; Paul Greenberg; Robert M A Hirschfeld; Robert Jin; Kathleen R Merikangas; Gregory E Simon; Philip S Wang
Journal:  Am J Psychiatry       Date:  2006-09       Impact factor: 18.112

2.  Incurring greater health care costs: risk stratification of employees with bipolar disorder.

Authors:  Richard A Brook; Krithika Rajagopalan; Nathan L Kleinman; James E Smeeding; Truman J Brizee; Harold H Gardner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 3.  Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement.

Authors:  Todd D Gould; Haim Einat
Journal:  Neurosci Biobehav Rev       Date:  2007-05-31       Impact factor: 8.989

4.  ECOLOGICALLY VALID LONG-TERM MOOD MONITORING OF INDIVIDUALS WITH BIPOLAR DISORDER USING SPEECH.

Authors:  Zahi N Karam; Emily Mower Provost; Satinder Singh; Jennifer Montgomery; Christopher Archer; Gloria Harrington; Melvin G Mcinnis
Journal:  Proc IEEE Int Conf Acoust Speech Signal Process       Date:  2014-07-14

Review 5.  Aripiprazole: in acute mania associated with bipolar I disorder.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Gender differences in health-related quality of life in patients with bipolar disorder.

Authors:  Maria Syl D de la Cruz; Zongshan Lai; David E Goodrich; Amy M Kilbourne
Journal:  Arch Womens Ment Health       Date:  2013-04-16       Impact factor: 3.633

7.  Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain.

Authors:  Monica Tafalla; Luis Salvador-Carulla; Jerónimo Saiz-Ruiz; Teresa Diez; Luis Cordero
Journal:  BMC Psychiatry       Date:  2010-04-28       Impact factor: 3.630

8.  Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection.

Authors:  Wissam El-Hage; Simon A Surguladze
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

9.  Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients.

Authors:  Antonio Drago; Barbara Monti; Diana De Ronchi; Alessandro Serretti
Journal:  Neuropsychobiology       Date:  2014-02-27       Impact factor: 2.328

10.  A systematic review of the evidence of the burden of bipolar disorder in Europe.

Authors:  Liberty Fajutrao; Julie Locklear; Jennifer Priaulx; Anne Heyes
Journal:  Clin Pract Epidemiol Ment Health       Date:  2009-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.